| 1/8/2021 |
Biocept (NASDAQ:BIOC) Rating Lowered to Sell at Zacks Investment Research |
theenterpriseleader.com |
... Zacks Investment Research cut shares of Biocept (NASDAQ:BIOC) from a hold rating to a sell rating in a report released on Monday, Zacks.com reports.According to Zacks, “Biocept, Inc. is a commercial stage oncology diagnostics company. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians. The company offers OncoCEE-BR (TM) test for ... |
| 1/5/2021 |
Zacks Investment Research Downgrades Biocept (NASDAQ:BIOC) to Sell |
slatersentinel.com |
... was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued on Monday, Zacks.com reports.According to Zacks, “Biocept, Inc. is a commercial stage oncology diagnostics company. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians. The company offers OncoCEE-BR (TM) test for ... |
| 1/5/2021 |
Biocept (NASDAQ:BIOC) Downgraded to “Sell” at Zacks Investment Research |
zolmax.com |
... Zacks Investment Research lowered shares of Biocept (NASDAQ:BIOC) from a hold rating to a sell rating in a report issued on Monday, Zacks.com reports.According to Zacks, “Biocept, Inc. is a commercial stage oncology diagnostics company. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians. The company offers OncoCEE-BR (TM) test for ... |
| 1/5/2021 |
Biocept (NASDAQ:BIOC) Downgraded by Zacks Investment Research to "Sell" |
Daily Political |
Zacks Investment Research lowered shares of Biocept (NASDAQ:BIOC) from a hold rating to a sell report released on Monday morning, Zacks.com reports. According to Zacks, “Biocept, Inc. is a commercial stage oncology diagnostics company. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians. The company offers OncoCEE-BR (TM) test for breast cancer ... |
| 12/4/2020 |
Onc.AI raises $6M Financing Round co-led by Blue Venture Fund and Accomplice |
vcaonline.com |
... sciences companies), Dr. Chen Fong (Co-Chair of the Global Strategy Board at Creative Destruction Lab), and Dr. Stanley Marks (Chairman of UPMC Hillman Cancer Center). “Onc.AI is developing an innovative comprehensive approach to oncology diagnostics which can help clinicians attain the full potential of precision oncology,” said Thomas Hawes, Managing Director of the Blue Venture Fund. “We believe Onc.AI can become the standard in oncology decision support and ... |
| 12/4/2020 |
Onc.AI raises $6M Financing Round co-led by Blue Venture Fund and Accomplice |
financialbuzz.com |
... sciences companies), Dr. Chen Fong (Co-Chair of the Global Strategy Board at Creative Destruction Lab), and Dr. Stanley Marks (Chairman of UPMC Hillman Cancer Center).“Onc.AI is developing an innovative comprehensive approach to oncology diagnostics which can help clinicians attain the full potential of precision oncology,” said Thomas Hawes, Managing Director of the Blue Venture Fund. “We believe Onc.AI can become the standard in oncology decision support and ... |
| 12/3/2020 |
|
malvern-online.com |
... sciences companies), Dr. Chen Fong (Co-Chair of the Global Strategy Board at Creative Destruction Lab), and Dr. Stanley Marks (Chairman of UPMC Hillman Cancer Center).“Onc.AI is developing an innovative comprehensive approach to oncology diagnostics which can help clinicians attain the full potential of precision oncology,” said Thomas Hawes, Managing Director of the Blue Venture Fund. “We believe Onc.AI can become the standard in oncology decision support and ... |
| 12/3/2020 |
Onc.AI raises $6M Financing Round co-led by Blue Venture Fund and Accomplice - Business Wire |
Business Wire |
... sciences companies), Dr. Chen Fong (Co-Chair of the Global Strategy Board at Creative Destruction Lab), and Dr. Stanley Marks (Chairman of UPMC Hillman Cancer Center).“Onc.AI is developing an innovative comprehensive approach to oncology diagnostics which can help clinicians attain the full potential of precision oncology,” said Thomas Hawes, Managing Director of the Blue Venture Fund. “We believe Onc.AI can become the standard in oncology decision support and ... |
| 11/3/2020 |
Biocept (NASDAQ:BIOC) Stock Rating Lowered by Zacks Investment Research |
Dakota Financial News |
... Investment Research cut shares of Biocept (NASDAQ:BIOC) from a buy rating to a hold rating in a report published on Friday morning, Zacks.com reports.According to Zacks, “Biocept, Inc. is a commercial stage oncology diagnostics company. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians. The company offers OncoCEE-BR (TM) test for ... |
| 11/1/2020 |
Zacks Investment Research Downgrades Biocept (NASDAQ:BIOC) to Hold |
Daily Political |
Biocept (NASDAQ:BIOC) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Friday, Zacks.com reports. According to Zacks, “Biocept, Inc. is a commercial stage oncology diagnostics company. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians. The company offers OncoCEE-BR ... |
| 11/1/2020 |
Zacks Investment Research Downgrades Biocept (NASDAQ:BIOC) to Hold |
Ticker Report |
Biocept (NASDAQ:BIOC) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Friday, Zacks.com reports.According to Zacks, “Biocept, Inc. is a commercial stage oncology diagnostics company. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians. The company offers OncoCEE-BR ... |
| 10/31/2020 |
Biocept (NASDAQ:BIOC) Cut to “Hold” at Zacks Investment Research |
techknowbits.com |
... Investment Research cut shares of Biocept (NASDAQ:BIOC) from a buy rating to a hold rating in a research report released on Friday, Zacks.com reports.According to Zacks, “Biocept, Inc. is a commercial stage oncology diagnostics company. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians. The company offers OncoCEE-BR (TM) test for ... |
| 10/30/2020 |
Biocept (NASDAQ:BIOC) Upgraded to Buy by Zacks Investment Research |
wkrb13.com |
upgraded shares of Biocept (NASDAQ:BIOC) from a hold rating to a buy rating in a report issued on Monday morning, Zacks.com reports. currently has $5.00 price objective on the medical research company’s stock.According to Zacks, “Biocept, Inc. is a commercial stage oncology diagnostics company. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide ... |
| 10/28/2020 |
Biocept (NASDAQ:BIOC) Lifted to Buy at Zacks Investment Research |
Dakota Financial News |
... objective on the medical research company’s stock. Zacks Investment Research ‘s price objective would suggest a potential upside of 12.87% from the company’s previous close.According to Zacks, “Biocept, Inc. is a commercial stage oncology diagnostics company. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians. The company offers OncoCEE-BR (TM) test for ... |
| 10/27/2020 |
Biocept (NASDAQ:BIOC) Downgraded by Zacks Investment Research to Hold |
wkrb13.com |
Zacks Investment Research downgraded shares of Biocept (NASDAQ:BIOC) from a buy rating to a hold rating in a research note issued to investors on Friday morning, Zacks.com reports.According to Zacks, “Biocept, Inc. is a commercial stage oncology diagnostics company. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians. The company offers OncoCEE ... |
| 10/27/2020 |
Biocept (NASDAQ:BIOC) Upgraded to “Buy” at Zacks Investment Research |
Ticker Report |
upgraded shares of Biocept (NASDAQ:BIOC) from a hold rating to a buy rating in a report published on Monday morning, Zacks.com reports. They currently have $5.00 target price on the medical research company’s stock.According to Zacks, “Biocept, Inc. is a commercial stage oncology diagnostics company. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to ... |
| 10/27/2020 |
Biocept (NASDAQ:BIOC) Upgraded to “Buy” by Zacks Investment Research |
techknowbits.com |
... price target on the medical research company’s stock. Zacks Investment Research ‘s price objective suggests a potential upside of 14.68% from the stock’s previous close.According to Zacks, “Biocept, Inc. is a commercial stage oncology diagnostics company. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians. The company offers OncoCEE-BR (TM) test for ... |
| 10/27/2020 |
Biocept (NASDAQ:BIOC) Upgraded to “Buy” by Zacks Investment Research |
slatersentinel.com |
... target on the medical research company’s stock. Zacks Investment Research ‘s price objective points to a potential upside of 14.68% from the stock’s previous close.According to Zacks, “Biocept, Inc. is a commercial stage oncology diagnostics company. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians. The company offers OncoCEE-BR (TM) test for ... |
| 10/26/2020 |
Biocept (NASDAQ:BIOC) Cut to Hold at Zacks Investment Research |
zolmax.com |
... Research cut shares of Biocept (NASDAQ:BIOC) from a buy rating to a hold rating in a research report released on Friday morning, Zacks.com reports.According to Zacks, “Biocept, Inc. is a commercial stage oncology diagnostics company. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians. The company offers OncoCEE-BR (TM) test for ... |
| 10/25/2020 |
Zacks Investment Research Downgrades Biocept (NASDAQ:BIOC) to Hold |
Ticker Report |
Biocept (NASDAQ:BIOC) was downgraded by from a “buy” rating to a “hold” rating in a report released on Friday, Zacks.com reports.According to Zacks, “Biocept, Inc. is a commercial stage oncology diagnostics company. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians. The company offers OncoCEE-BR (TM) test for breast cancer. Biocept ... |